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Introduction: In this study the protective effects of Silymarin was investigated against thioacetamide 
(TAA) induced hepatotoxicity in rat.
 Methods: In an experimental study 24 male Wistar rats were designated in four equal groups as follows: 
Control group, the group treated with thioacetamide (TAA), Silymarin (400 mg/kg for 3 weeks) + TAA 
(400 mg/kg), TAA (400 mg/kg) + Silymarin (400 mg/kg for 3 weeks). The levels of serum aspartate 
transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) lactate dehydrogenase 
(LDH) and total bilirubin were measured to assess the hepatotoxicity and hepatoprotection. 
Results: TAA signiﬁcantly increased AST, ALT, ALP, LDH and bilirubin. Treatment by Silymarin 
caused a signiﬁcant reduction in serum levels of AST, ALT, ALP, LDH and bilirubin contents.
Conclusion: The results indicate a protective effect for Silymarin against thioacetamide induced 
hepatotoxicity which might be due to its ability to block the bioactivity of thioacetamide.
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Introduction
Liver cancer is one of common malignancies in the world, 
especially in Asia and Africa (1). Liver cirrhosis is induced 
by chronic liver injury, i.e. by viral hepatitis, alcoholic 
hepatitis, and parasitic diseases. This cirrhosis in turn, 
causes an imbalance in the proliferation of hepatocytes (2). 
Thioacetamide (TAA) is a classic hepatotoxic reagent used for 
the induction of liver cirrhosis (3). Ledda-Columbano et al. 
(1991) reported that thioacetamide induced apoptosis in the 
rat liver based on histochemical observations (4). In addition, 
it has been suggested that thioacetamide can also stimulate the 
DNA synthesis and mitosis in liver for hepatic regeneration 
(5). Indeed, the results of several studies have demonstrated 
beneﬁcial effect of antioxidants in protecting the liver against 
TAA-induced injury (6,7). Antioxidants are expected to 
protect the liver from oxidative stress (8). The plant is known 
to possess antitumor (9,10), free radical scavenging and lipid 
peroxidation (11) activities. Numerous studies with have 
been carried out to evaluate Silymarin/Silibinin on patients 
with adverse liver conditions (12). Silybum marianum L.  is a 
member of the family (Asteracae) widely used in traditional 
European medicine (12). 
Silymarin, a polyphenolic ﬂavonoid isolated from milk 
thistle, primarily consists of four isomeric componds of active 
ﬂavonolignans: silychristin, silydianin, and two groups of 
diastereoisomeric ﬂavonolignans, silibinin, and isosilibinin 
(13). Silibinin, a ﬂavanone, is the major and the most active 
component present in Silymarin that represents about 60–70% 
(14). Silymarin has clinical applications in the toxic hepatitis 
treatment, fatty liver, cirrhosis, ischaemic injury, radiation 
toxicity and viral hepatitis as a result of its antioxidative, anti-
lipid-peroxidative, antiﬁbrotic, anti-inﬂammatory, immuno-
modulating and even liver regenerating effects (15). In 
experiments on animals, Silymarin and Silibinin are shown 
to protect rat or mouse liver against hepatotoxicity induced by 
acute thioacetamide (16). It could also be useful in preventing 
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a wide range of carcinogen and tumor  promoter-induced 
cancers (17), Silymarin is a popular herbal product marketed 
to treat liver  disorders (18).
This study was designed to evaluate the hepatoprotective and 
antioxidant potentials of Silymarin against thioacetamide 
induced liver injury in rats. 
Materials and Methods
Animals and Treatment
Twenty four male Wistar rats (200-250 g of body weight) were 
prepared from animal house of Isfahan University of Medical 
Sciences and were kept under controlled temperature (23 ± 2 
°C) and 12:12 h light-dark cycle conditions. The animals were 
divided into four groups.
Group 1: control. 
Group 2: injected with TAA (400 mg/kg) for 2 weeks.
Group 3: injectd with TAA (400 mg/kg) and then Silymarin 
(400 mg/kg) for 3 weeks.
Group 4: injected  with Silymarin (400 mg/kg b.w) for 3 weeks 
and then with TAA (400 mg/kg).
At the end of the experiment the rats were sacrificed by 
anesthetic overdose and samples of serum and liver were 
collected.
Biochemical evaluation
Serum samples obtained from the rats were analyzed for 
alanin aminotransferase (ALT), aspartate aminotransferase 
(AST), alkalin phosphatase (ALP), lactate dehydrogenase 
(LDH), total cholesterol (Chol), LDL-cholesterol (LDL-C), 
HDL-cholesterol (HDL-C) and triglyceride (TG). Blood 
samples were collected from inferior cava vein after anesthesia 
and measured using special kits (DiaSys, Germany) which 
utilized the colorimetric method, in an autoanalyzer (Hitachi 
autoanalyzer, Hitachi Co., Tokyo). Bilirubin was also 
measured.
Histopathological analysis
The tissues were ﬁxed in 10% buffered formalin, embedded in 
parafﬁn, sectioned and stained with hematoxylin and eosin 
(H&E) for histological studies.
Statistical analysis
The data obtained was subjected to one way ANOVA and 
Tukey’s multiple comparison test using SPSS statistical 
package (Version 13.0). Values were expressed as mean± SD. 
P value p< 0.05 was considered significant.
Results
The daily access to food and water was controlled in the period 
and no difference in body weight gain was observed among all 
groups at the end (Table 1).
The levels of liver enzymes, bilirubin and lipids factors in 
serum of control group had no signiﬁcant deference in the 
beginning of the study. Rats treated with Thioacetamide 
(TAA) developed signiﬁcant hepatic damage as indicated 
from elevated serum levels of hepatospeciﬁc enzymes AST, 
ALT, ALP and LDH (Table 1). Serum bilirubin level was 
enhanced by TAA treatment. Serum total cholesterol (Chol), 
HDL-cholesterol (HDL-C) and triglyceride (TG) levels 
were considerably reduced and LDL-cholesterol (LDL-C) 
increased by TAA treatment (Table 1).  The treatment by 
Silymarin produced a signiﬁcant reduction in serum enzyme 
levels (AST, ALT, ALP , LDH ) and  reduction in bilirubin 
content (Table 1). The plasma AST, ALT, ALP and LDH 
were significantly decreased in Group 4 (Silymarin and then 
thioacetamide) compared to the thioacetamide group and 
were even comparable to the control group and a reduction 
in bilirubin content (Table 1). Histopathological evaluation 
indicates that compared to normal group (Figure 1), TAA 
caused focal necrosis, increase in mitosis at cells, apoptosis, 
abnormally mitosis, inflammation at portal space and large 
Table 1. Effect of Thioacetamide and silymarin treatment on rat body weight, liver weight, and biochemical parameters
Parameters Groups
control TAA TAA+Silymarin Silymarin +TAA
ALT(U/L) 148±26.058 767±16.971* 89.60±17.658** 202.75±4.992**
AST(U/L) 184.33±62.324 653±53.033* 125.80±6.301** 296.25±61.402**
ALP(U/L) 614.67±196.398 1593.50±214.253* 623.6±160.982** 1199.60±172.216**
LDH(U/L) 1116.33±74.272 1269.50±6.364 862.60±298.458** 1799±130.186**
TG(mg/dl) 29.33±16.563 11±1.414 48.20±13.274** 12.75±2.217
cho(mg/dl) 88.67±13.051 64.50±3.536* 77.4±4.278** 81.20±12.518
LDL(mg/dl) 10±2.646 16±0.0 12.25±2.168** 20.60±2.608
HDL(mg/dl) 42.33±5.859 30±5.657 44.40±2.408** 37.80±8.672
Bilirobin(mg/dl) 0.4833±0.028 1.05±0.63 0.63±0.044 0.55±0.141
 BW (g) 244.76±32.712 191.93±10.909 196.84±28.047 216.26±21.257
LW (g) 8.47±0.32 7.38±0.72 7.38±1.21 7.68±0.64
LW/BW (%) 3.46±0.2 3.84±0.1 3.74±0.3 3.55±0.1
Note. Body and liver weights were recorded at the time of killing. Abreviation are Alanin aminotransferase (ALT), Aspartataminotransferase (AST), 
Alkalinphosphatase (ALP), Lactate dehydrogenase (LDH), total cholesterol (Chol), LDL-cholesterol (LDL-C), triglyceride (TG) and HDL-cholesterol (HDL-C), body 
weight (BW) and liver weight (LW). Data are expressed as the mean ± SD. 
*P<0.05 vs. controls.
**P<0.05 vs. TAA 
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nucleus (Figure  2). Necrosis, a more severe form of injury 
was markedly prevented by natural Silymarin especially 
by 400 mg/kg body weight (Figure 3). In the Silymarin 
treatment group, some cells had large nucleus but there were 
not apoptosis and mitosis (Figure  4) and in the Silymarin 
prevention group +TTA, and TTA+ Silymarin  these changes 
were not observable. 
Discussion 
Thioacetamide (TAA) is widely used for experimentally 
induced liver injury. While acute TAA application results in 
hepatitis (19), chronic TAA application has been shown to 
cause liver cirrhosis (20). It has been reported that oxidative 
stress contributes significantly to the pathogenesis of TAA-
induced hepatitis and cirrhosis (20). However, the mechanism 
of oxidative stress in TAA hepatotoxicity is still unclear. TAA 
S-oxide and TAA S-dioxide are the essential very reactive 
compounds produced during cytochrome-P450-mediated 
oxidation of TAA, in addition to the free radicals (21). 
Thioacetamide can be metabolized in more toxic metabolite 
and thioacetamide S-oxide, by P450 enzyme (22). In 
addition, well-known P450 inhibitor, SKF-525A, is protected 
against the hepatic necrosis caused by thioacetamide and 
thioacetamide S-oxide, suggesting that both thioacetamide 
and thioacetamide S-oxide are activated by hepatic mixed-
function oxidase enzymes to a hepatotoxic compound (22). 
The P450 2B enzyme is implicated to selectively metabolize 
thioacetamide to its S-oxide metabolite (23).  In this study, 
a sub-lethal dose of TAA (400 mg/kg) was used for 10 days, 
because TAA-induced liver injury has been reported to be 
evident at this time in experimental studies. Signiﬁcant 
increases in AST, ALT, ALP, LDH plasma and increase in 
bilirubin level as well as histopathological liver necrosis 
ﬁndings were observed. In this study, increase in AST, ALT, 
Figure 2. Liver histopathology of group 2 (B), Animals were injected injected (i.p.) TAA (400 mg/kg) for 2 weeks; Ba: Abnormal mitosis, Bb: 
Apoptosis, Bc: Mitosis Bd: Inflammation around the port area; 40X 
  
ALP, LDH and bilirubin levels induced by thioacetamide was 
signiﬁcantly reduced by Silymarin. This hepatoprotective 
activity might be due to its effect against cellular leakage 
and loss of functional integrity of the cell membrane in liver. 
Silymarin is a popular herbal product marketed to treat liver 
disorders (18). The results from the studies indicate that 
Silymarin has good hepatoprotective and has antioxidant 
potential against diethylnitrosamine induced hepatocellular 
damage in rats (24-26).
In the recent years, increasing body of evidence has 
underscored the cancer preventive efficacy of Silymarin in 
both in vitro and in vivo animal models of various epithelial 
cancers (25). Silybin acts mainly as an effective radical 
scavenger (antilipoperoxidant) (26) and as an antioxidant, 
as well (27). Recently, the results of numerous experimental 
studies strongly suggest that Silybin (and/or Silymarin) 
hepatoprotective effects are mainly due to free radical 
scavenging (28). Silibinin as an effective anti-cancer and 
chemopreventive agent in various epithelial cancer models 
Figure 1.  Liver histopathology of control group, 40X
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plasma levels of cholesterol in normal rats; however, it does 
reduce phospholipid levels, especially those transported in 
LDL (33). Silymarin and quercetin are polyphenolic ﬂavonoids 
that increase cell resistance to lipid peroxidation (34).
This study demonstrates that the hepatoprotective effect 
of silymarin against thioacetamide-induced hepatotoxicity 
might be a result of multiple mechanisms. It is thought that 
Silymarin has beneﬁcial effect on liver, but more detailed 
biochemical and histopathological studies are necessary in 
order to conﬁrm this effect in thioacetamide-induced toxicity. 
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